ETC
RXRX icon

Exchange Traded Concepts’s Recursion Pharmaceuticals RXRX Stock Holding History

Exchange Traded Concepts’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,624
Closed -$98.5K – 1489
2025
Q1 		$98.5K Sell
18,624
-32,137
-63% -$234K ﹤0.01% 1168
2024
Q4 		$343K Buy
50,761
+25,579
+102% +$172K 0.01% 833
2024
Q3 		$166K Buy
25,182
+5,021
+25% +$36K ﹤0.01% 1020
2024
Q2 		$151K Sell
20,161
-6,271
-24% -$54.7K ﹤0.01% 906
2024
Q1 		$264K Buy
26,432
+10,073
+62% +$112K 0.01% 847
2023
Q4 		$161K Buy
16,359
+4,148
+34% +$29.6K ﹤0.01% 820
2023
Q3 		$93.4K Sell
12,211
-2,089
-15% -$20.8K ﹤0.01% 921
2023
Q2 		$107K Buy
+14,300
New +$100K ﹤0.01% 934

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Exchange Traded Concepts's RXRX Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 18,624 shares — an estimated $98.5K sold.

Exchange Traded Concepts first reported a position in RXRX in Q2 2023 and held it in 8 quarters. The position peaked at $343K in Q4 2024. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 18,624 Recursion Pharmaceuticals shares in Q2 2025, an estimated $98.5K.
  • Exchange Traded Concepts first reported a position in Recursion Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Recursion Pharmaceuticals position peaked at $343K in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.